Prog

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, today announcedsignificant progress in validating novel, effective products forthe potential treatment of asthma. In studies of its proprietaryPRS-060 Anticalin(R) candidate, the Company reports that theprotei...

Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

NEWTON, Mass.--(BUSINESS WIRE)--Jul 9, 2007 - Pro-Pharmaceuticals,Inc. (Amex: PRW), a company "Advancing Drugs ThroughGlycoscience(R)", today updated the progress of its Phase IIclinical trial for first-line treatment of metastatic, unresectablecolorectal cancer patients who are unable to tolerate irinotecanand/or oxaliplatin, and its Phase II clinical trial for first-linetreatment of bilia...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - ElixirPharmaceuticals, Inc., today announced the presentation of two setsof preclinical data demonstrating that ghrelin antagonism may be apotential method for future treatment of a range of metabolicdisorders. These data demonstrated a variety of beneficialmetabolic effects, notably decreasing body weight, improvements inblood glucose and i...

Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology

FREISING-WEIHENSTEPHAN, Germany, June 21, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing Anticalins(R), anovel class of targeted human protein therapeutics, announced todaythat its proprietary Duocalin(R) technology has successfullydemonstrated dual targeting potential. Commenting on this development, Dr Andreas Hohlbaum, Director ofScience and Preclinical D...

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

Summary: Pharmexa-Epimmune, the U.S.-based subsidiary ofPharmexa A/S, presents selected data from its influenza vaccineprogram today at the Influenza Conference entitled, "Options forthe Control of Influenza VI," held in Toronto, Ontario, Canada. Thedata show that a "universal" vaccine designed to inducecell-mediated immune responses can protect transgenic mice againstlethal experimental...

Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting

Company-Sponsored Investor Briefing and Webcast to FollowPresentation DANBURY, Conn., June 20, 2007 /PRNewswire-FirstCall/ -- BiodelInc. today announced plans to present clinical results of itsleading product candidate, VIAject(TM), at the 67th Annual AmericanDiabetes Association (ADA) Scientific Sessions, to be held inChicago, June 22 through June 26. Biodel's oral presentation at...

Amylin Pharmaceuticals to Present New Data from Broad Diabetes and Obesity Programs at ADA 2007

SAN DIEGO, June 19, 2007 /PRNewswire-FirstCall/ -- AmylinPharmaceuticals, Inc. today announced that data featuring itsapproved diabetes drugs, BYETTA(R) (exenatide) injection andSYMLIN(R) (pramlintide acetate) injection, and its pipelinecandidates will be presented at the American Diabetes Association's(ADA) 67th Annual Scientific Sessions being held in Chicago, ILfrom June 22 to 26. The...

Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting

MONTREAL, QUEBEC--(CCNMatthews - June 14, 2007) - AmbriliaBiopharma Inc. (TSX:AMB), a biopharmaceutical company developingnovel small molecules and peptides to treat infectious diseases andcancer, held its Annual General and Special Meeting today, duringwhich the data reported yesterday on its novel series of HIVintegrase inhibitors and recent developments were highlighted. Themeeting wa...

Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-FiteBioPharma (TASE:CFBI), a biotechnology company traded on the TelAviv Stock Exchange Exchange, proceeds with the development of itsthird drug CF502; this is in addition to CF101, which is currentlyin clinical trials and CF102, which is in preclinical phases. Thisweekend Can-Fite will present at the EUALR annual congress ofrheumato...

CuraGen Presents Update on Clinical Development Program for Belinostat

- Clinical activity reported against CTCL, PTCL and Ovarian Cancers- BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ -- CuraGenCorporation , a clinical-stage biopharmaceutical company focused ononcology, presented today an update on the clinical developmentprogram for belinostat, a histone deacetylase (HDAC) inhibitor, andreported updated results suggesting clinical activity of beli...

Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression

- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...

Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer

CHICAGO - June 3, 2007 - Schering-Plough Corp. announced resultsfrom a Phase III study that showed maintenance chemotherapy withCaelyx (pegylated liposomal doxorubicin hydrochloride)significantly prolonged time to progression (TTP) in patients withmetastatic breast cancer with infrequent and manageable clinicaltoxicity after first-line chemotherapy. These data were presentedtoday at the...

Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting

* Preclinical study evaluating a clinically relevant model ofnormal human skin found that Menadione was the only agent capableof abrogating the cytotoxic effect of erlotinib * Phase I singleagent Marqibo(r) showed OPTISOME(tm) agent was generally welltolerated in metastatic melanoma patients with an adverse eventprofile similar to conventional vincristine SOUTH SAN FRANCISCO, Calif...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of therandomized phase III EORTC 40983 Intergroup study, or EPOC study,demonstrate for the first time that peri-operative (pre and postsurgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) incombination with a standard chemotherapy regimen for co...

Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an internationalbiopharmaceutical company focusing on the research, development andcommercialization of targeted anti-cancer drugs, today announcedthat they presented data from a Phase I clinical trial of theiranti-cancer compound, DTS-201, at the 43rd Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago, USA. DTS-20...

OXiGENE Abstracts Published in ASCO Program

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 1, 2007 - OXiGENE, Inc.(NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceuticalcompany developing novel therapeutics to treat cancer and eyediseases, announced today the publication of two abstracts in the2007 Annual Meeting program distributed this afternoon at theAnnual Meeting of the American Society of Clinical Oncology (ASCO)in Chicago, IL.<p...

DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp

CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECTCorporation announced today that Voyager Pharmaceutical hasprovided its shareholders with an update on its truncated Phase 3clinical trial for Memryte, an investigational drug for thetreatment of Alzheimer's disease. Voyager has informed itsshareholders that they have observed positive outcome trends amongwomen, but no posit...

SkyePharma and Sciele Pharma Announce Successful Completion of New Sular Formulation Clinical Trial Programme

LONDON, UK and ATLANTA, US, May 14, 2007 - SkyePharma PLC(LSE:SKP; NASDAQ:SKYE) and Sciele Pharma. Inc. (NASDAQ:SCRX) todayannounce the successful completion of the clinical trial programmefor the new formulation of Sular, a calcium channel blocking agent for the treatment of high blood pressure.The study results showed that the new Sular formulatio...

Sciele Pharma Announces Successful Completion of New Sular Formulation Clinical Trial Program

ATLANTA--(BUSINESS WIRE)--May 14, 2007--Sciele Pharma, Inc.(NASDAQ:SCRX) today announced the successful completion of theclinical trial program for its new Sular formulation. The studyresults showed that the new Sular formulation is bioequivalent toSciele's currently marketed Sular. The new Sular formulationutilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which is designed t...

Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ --Viragen, Inc. and Viragen International, Inc. today announcedresults from a sponsored in vitro study conducted at UmeaUniversity in Sweden, which found that Multiferon(R) (multi-subtype, human alpha interferon) suppressed development ofresistant human melanoma clones to a far greater degree thanrecombinant alpha interferon. The stud...

Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting

Statistically Significant Improvements in Function in Spinal CordInjury Model With ZFP TF Treatment RICHMOND, Calif., May 03, 2007 /PRNewswire-FirstCall/ -- SangamoBioSciences, Inc. announced today the presentation of preclinicaldata from its ZFP Therapeutic(TM) program in nerve regeneration atthe Fourteenth Annual Conference of the American Society for NeuralTherapy and Repair. The data...

Quest PharmaTech's Prostate Cancer Program Update

Trading Symbol: QPT: TSX Venture Exchange EDMONTON, May 02, 2007 /PRNewswire-FirstCall/ - Quest PharmaTechInc. ("Quest" or the "Company") Quest is pleased to provide anupdate on the pre-clinical development of SL052 for the treatmentof prostate cancer. Prostate cancer is the second leading cause of cancer death inAmerican men with approximately 230,000 new cases and 30,000 deathspe...

Pediatric Academic Societies' Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc.(Nasdaq: MEDI) today announced that seven abstracts will bepresented at the 2007 Pediatric Academic Societies' (PAS) AnnualMeeting demonstrating the company's commitment to advancing thescience of pediatric medicine. Data are from studies pertaining toMedImmune's approved and development-stage products, including bothmonoclon...

Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 1, 2007 - ProgenicsPharmaceuticals, Inc. (NASDAQ: PGNX) today announced positiveresults from the first clinical trial of its investigational drug,PRO 140, in individuals infected with the human immunodeficiencyvirus (HIV), the causative agent of AIDS. Patients receiving asingle 5.0 mg/kg dose of PRO 140 achieved an average maximumdecrease of viral conce...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

Peregrine Pharmaceuticals Highlights Significant Advances in the Company's Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting

- New Study Demonstrated the Clinical Potential of Peregrine'sUnique Selective Anti-VEGF Antibodies, Which Were as Effective asAvastin(R) in Animal Cancer Models TUSTIN, Calif., April 20, 2007 /PRNewswire-FirstCall/ --Peregrine Pharmaceuticals, Inc. , a clinical stagebiopharmaceutical company developing targeted monoclonal antibodiesfor the treatment of cancer and hepatitis C virus infect...

Spectrum Pharmaceuticals Announces Data From Three Oncology Programs Presented at the American Association of Cancer Research Annual Meeting

1 EOquin Instillation Immediately Following Transurethral Resectionis Well Tolerated in Phase 2b Bladder Cancer Study IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ --Spectrum Pharmaceuticals, Inc., today announced results of a Phase2b study of EOquin, in non-invasive bladder cancer and thepresentation of preclinical data of SPI (IRL)-1620 and satraplatinat the annual meeting of th...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonalantibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL)were the focus of 44 total presentations at the recently concluded98th Annual Meeting of the American Association for Cancer Research(AACR), including seven oral presentations and 37 posters. Important ERBITUX(R) (cetuximab) clinical data were the focus oftwo back-to...

Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program

NEW YORK--(BUSINESS WIRE)--Apr 18, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) announced data from preclinical evaluation of thecompany's drug candidate INNO-206, a doxorubicin prodrug fortreatment of a variety of tumor types. Researchers found thatINNO-206, a form of doxorubicin that attaches to circulatingalbumin and becomes activated once located at the tumor site, ismuch better to...

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, 2007 - AlnylamPharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeuticscompany, announced today at the American Association for CancerResearch (AACR) 2007 Annual Meeting that it will advance asystemically delivered RNAi therapeutic, ALN-VSP01, for thetreatment of liver cancer and potentially other solid tumors as anew development program. A...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...

Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective

- Phase 3 Patient Enrolment Planned for Second Half of 2007 - BRISBANE, Australia, April 16, 2007 /PRNewswire-FirstCall/ --Progen Pharmaceuticals Limited today announced the final stage 1results of its Phase 2 trial of PI-88 in patients who hadpreviously undergone surgical removal of liver cancer. The 48 weekdata demonstrated that 160 mg of PI-88 showed an improvement indisease-free rate,...

Data supporting three Antisoma programmes presented at AACR

LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces thatpreclinical data supporting three of its drugs are presented thisweek at the Annual Meeting of the American Association of CancerResearch (AACR). AS1404-Avastin-paclitaxel triple combination highly effectiveAntisoma's scientists have for the first time evaluated a triplecombination of the Company's vascular disrupting a...

Rigel to Present New Research Programs at AACR Meeting

Focus on Rigel's Extensive Oncology Portfolio SOUTH SAN FRANCISCO, Calif., April 16, 2007/PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. todayannounced the presentation of four research projects aimed atidentifying small molecule inhibitors of select kinases aspotential therapeutics for certain types of cancers and otherdisorders. Rigel scientists will give the presentations during...

Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 10, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB:IVPH) today announced that interim data from a Phase Itrial of INNO-406, an orally bioavailable dual Bcr-Abl andLyn-kinase inhibitor for Gleevec-resistant or treatment-intolerantchronic myelogenous leukemia, will be presented at the AmericanAssociation for Cancer Research Annual Meeting. Additionally,preclinical...